The United Arab Emirates has achieved a significant medical milestone by becoming the first country globally to authorize an oral medication for the treatment of non-segmental vitiligo. The Emirates Drug Establishment (EDE) officially approved RINVOQ (upadacitinib) for use in adolescents and adults aged 12 and older who require systemic therapy. This breakthrough offers a convenient once-daily pill option for patients, marking a major shift in how this autoimmune-related skin condition, which causes pigment loss and white patches, is managed.

Beyond providing a new therapeutic pathway, this approval underscores the UAE’s commitment to staying at the forefront of pharmaceutical innovation and regulatory excellence. While existing treatments for vitiligo often rely on light therapy or topical applications, this systemic approach provides a vital alternative for those needing broader care. Health authorities are encouraging individuals who notice skin pigment changes to consult specialists promptly, as early diagnosis remains key to navigating the diverse treatment options now available in the region.